Spero pays $54.5M to terminate HCR revenue interest agreement, regains Tebi asset rights

Spero Therapeutics, Inc.

Cash payment of $54.5M (exact $54,484,895) on June 7, 2022 to terminate HCR financing agreement and release all liens.
All rights to tebipenem (Tebi) assets revert to Spero; company previously ceased Tebi commercialization on May 3, 2022.
Contingent additional payment of up to $10M+ if a change of control occurs by Dec 31, 2022, based on equity value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.